EKTAY vs NEOG
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EKTAY is a Sell and NEOG is a StrongSell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EKTAY’s FA Score shows that 1 FA rating(s) are green whileNEOG’s FA Score has 1 green FA rating(s).
- EKTAY’s FA Score: 1 green, 4 red.
- NEOG’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EKTAY’s TA Score shows that 3 TA indicator(s) are bullish while NEOG’s TA Score has 6 bullish TA indicator(s).
- EKTAY’s TA Score: 3 bullish, 5 bearish.
- NEOG’s TA Score: 6 bullish, 5 bearish.
Price Growth
EKTAY (@Medical Specialties) experienced а -5.54% price change this week, while NEOG (@Medical Specialties) price change was -10.04% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.
Reported Earning Dates
NEOG is expected to report earnings on Dec 17, 2024.
Industries' Descriptions
@Medical Specialties (-4.23% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| EKTAY | NEOG | EKTAY / NEOG | |
| Capitalization | 3.09B | 3.42B | 90% |
| EBITDA | 2.49B | 189M | 1,315% |
| Gain YTD | -28.471 | -27.399 | 104% |
| P/E Ratio | 34.01 | 150.80 | 23% |
| Revenue | 16.9B | 919M | 1,839% |
| Total Cash | 3.27B | 230M | 1,422% |
| Total Debt | 6.67B | 889M | 750% |
EKTAY | NEOG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 64 | 87 | |
PRICE GROWTH RATING 1..100 | 83 | 57 | |
P/E GROWTH RATING 1..100 | 70 | 3 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EKTAY's Valuation (3) in the null industry is significantly better than the same rating for NEOG (96) in the Medical Specialties industry. This means that EKTAY’s stock grew significantly faster than NEOG’s over the last 12 months.
EKTAY's Profit vs Risk Rating (100) in the null industry is in the same range as NEOG (100) in the Medical Specialties industry. This means that EKTAY’s stock grew similarly to NEOG’s over the last 12 months.
EKTAY's SMR Rating (64) in the null industry is in the same range as NEOG (87) in the Medical Specialties industry. This means that EKTAY’s stock grew similarly to NEOG’s over the last 12 months.
NEOG's Price Growth Rating (57) in the Medical Specialties industry is in the same range as EKTAY (83) in the null industry. This means that NEOG’s stock grew similarly to EKTAY’s over the last 12 months.
NEOG's P/E Growth Rating (3) in the Medical Specialties industry is significantly better than the same rating for EKTAY (70) in the null industry. This means that NEOG’s stock grew significantly faster than EKTAY’s over the last 12 months.
| EKTAY | NEOG | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 52% | 3 days ago 62% |
| Stochastic ODDS (%) | 3 days ago 72% | 3 days ago 61% |
| Momentum ODDS (%) | 7 days ago 63% | 3 days ago 55% |
| MACD ODDS (%) | N/A | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 74% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 75% |
| Advances ODDS (%) | N/A | 7 days ago 69% |
| Declines ODDS (%) | 3 days ago 59% | 3 days ago 75% |
| BollingerBands ODDS (%) | 3 days ago 74% | 3 days ago 76% |
| Aroon ODDS (%) | 3 days ago 61% | 3 days ago 71% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GTMIX | 15.15 | 0.02 | +0.13% |
| GMO International Opportunistic Val III | |||
| MIZIX | 8.41 | -0.06 | -0.71% |
| MassMutual International Eq I | |||
| GSQTX | 43.34 | -0.38 | -0.87% |
| Goldman Sachs Small Cap Value Inv | |||
| VSMAX | 118.05 | -1.27 | -1.06% |
| Vanguard Small Cap Index Adm | |||
| SGRKX | 44.77 | -0.94 | -2.06% |
| Allspring Growth Admin | |||
EKTAY and
Correlation & Price change
A.I.dvisor tells us that EKTAY and SAUHY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EKTAY and SAUHY's prices will move in lockstep.
| Ticker / NAME | Correlation To EKTAY | 1D Price Change % | ||
|---|---|---|---|---|
| EKTAY | 100% | -1.23% | ||
| SAUHY - EKTAY | 31% Poorly correlated | -1.84% | ||
| SMMNY - EKTAY | 29% Poorly correlated | +0.45% | ||
| PHG - EKTAY | 29% Poorly correlated | +0.39% | ||
| GNGBY - EKTAY | 26% Poorly correlated | -2.67% | ||
| NEOG - EKTAY | 26% Poorly correlated | -0.27% | ||
More | ||||
NEOG and
Correlation & Price change
A.I.dvisor indicates that over the last year, NEOG has been loosely correlated with CRL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NEOG jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To NEOG | 1D Price Change % | ||
|---|---|---|---|---|
| NEOG | 100% | -0.27% | ||
| CRL - NEOG | 47% Loosely correlated | -4.65% | ||
| AZTA - NEOG | 45% Loosely correlated | -2.62% | ||
| VCYT - NEOG | 44% Loosely correlated | -2.97% | ||
| MASS - NEOG | 44% Loosely correlated | +0.42% | ||
| TWST - NEOG | 43% Loosely correlated | -5.31% | ||
More | ||||